1. Enhancement of episodic memory and reduction of intrusion errors are considered as the most characteristic outcome of cholinergic drugs administration in AD patients. 2. Since the nootropic drugs Piracetam and Oxiracetam are deemed to act through a cholinergic mechanism, we checked whether AD patients treated with these drugs would show the same pattern of neuropsychological improvement. 3. Results were negative, since (a) episodic memory showed a similar degree of improvement both in patients treated with these drugs and in patients treated with placebo; (b) the number of intrusions tended to increase, rather than to decrease, after the treatment period
In order to have a correct evaluation of the activity of a nootropic drug, the criteria adopted for ...
The current research methods, findings and questions that are being addressed in studies of the phar...
Cholinergic precursors have represented the first approach to counter cognitive impairment occurring...
1. Enhancement of episodic memory and reduction of intrusion errors are considered as the most chara...
In the last 20 years a cholinergic dysfunction has been the major working hypothesis for the pharmac...
Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and cognitive loss,...
Alzheimer's disease is one of the most common causes of mental deterioration in elderly people, acco...
Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and cognitive loss,...
Alzheimer’s disease (AD) is a neurodegenerative disease characterized bymemory and cognitive loss, a...
In early Alzheimer's disease, which initially presents with progressive loss of short-term memory, n...
The primary pathology in Alzheimer's disease (DAT) occurs in the basal forebrain cholinergic system ...
Although the exact pathogenesis of Alzheimer’s disease (AD) remains unclear, the widespread loss of ...
The observations of the loss of cholinergic function in neocortex and hippocampus in Alzheimer's dis...
The clinical benefits of nootropics in the treatment of cognitive decline has been either limited or...
The cholinergic hypothesis suggests that Alzheimer's disease (AD) results from a selective loss in c...
In order to have a correct evaluation of the activity of a nootropic drug, the criteria adopted for ...
The current research methods, findings and questions that are being addressed in studies of the phar...
Cholinergic precursors have represented the first approach to counter cognitive impairment occurring...
1. Enhancement of episodic memory and reduction of intrusion errors are considered as the most chara...
In the last 20 years a cholinergic dysfunction has been the major working hypothesis for the pharmac...
Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and cognitive loss,...
Alzheimer's disease is one of the most common causes of mental deterioration in elderly people, acco...
Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and cognitive loss,...
Alzheimer’s disease (AD) is a neurodegenerative disease characterized bymemory and cognitive loss, a...
In early Alzheimer's disease, which initially presents with progressive loss of short-term memory, n...
The primary pathology in Alzheimer's disease (DAT) occurs in the basal forebrain cholinergic system ...
Although the exact pathogenesis of Alzheimer’s disease (AD) remains unclear, the widespread loss of ...
The observations of the loss of cholinergic function in neocortex and hippocampus in Alzheimer's dis...
The clinical benefits of nootropics in the treatment of cognitive decline has been either limited or...
The cholinergic hypothesis suggests that Alzheimer's disease (AD) results from a selective loss in c...
In order to have a correct evaluation of the activity of a nootropic drug, the criteria adopted for ...
The current research methods, findings and questions that are being addressed in studies of the phar...
Cholinergic precursors have represented the first approach to counter cognitive impairment occurring...